Dr. Silvon has driven profitable, pragmatic life sciences operations over the breadth of small and large molecule drug development; creating, fixing and growing multiple high science, heavily regulated businesses as a senior executive for Charles River Labs, Bioanalytical Systems and ICI/Zeneca. He orchestrated six acquisitions in synthesis, bioanalysis, preclinical services and Phase I/IIa human clinical trials services: integrating them and later running three, long-term. As VP Global Biopharmaceutical Services for Charles River Labs, he restructured and consolidated five global sites into a worldwide leader in molecular biology, virology and microbiology services. Mike currently fills advisory, operating and board roles in the Contagion Prevention Consortium, orchestrating epidemiologically meaningful antibody testing among partner labs; Molecular Targeting Technologies, a clinical stage company developing four radiotheranostics for multiple cancers; Chronic Airways Therapeutics, repurposing an established therapeutic for severe asthma; and Spark Insights, delivering high-impact health data from real-world, personal and trusted patient engagement.
Dr. Silvon received a Ph.D. in physical organic Chemistry from the University of Vermont and completed postdoctoral fellowships at Penn State in organometallic chemistry and the Technischen Universität München in inorganic chemistry, the latter as a fellow of the Alexander von Humboldt Stiftung working with Nobel Prize recipient Prof. Dr. Ernst O. Fisher.
